Literature DB >> 29769260

Bim regulates the survival and suppressive capability of CD8+ FOXP3+ regulatory T cells during murine GVHD.

Kimberle Agle1, Benjamin G Vincent2,3, Clint Piper1, Ludovic Belle1, Vivian Zhou1, Warren Shlomchik4, Jonathan S Serody2, William R Drobyski1.   

Abstract

CD8+ Foxp3+ T cells (Tregs) are a potent regulatory population whose functional and ontological similarities to CD4+ Fox3+ T cells have not been well delineated. Using an experimental model of graft-versus-host disease (GVHD), we observed that CD8+ Tregs were significantly less potent than CD4+ Tregs for the suppression of GVHD. To define the mechanistic basis for this observation, we examined the T-cell repertoire and the transcriptional profile of in vivo-derived CD4+ and CD8+ Tregs that emerged early during this disease. Polyclonal and alloantigen-induced CD8+ Tregs had repertoire diversity that was similar to that of conventional CD8+ T cells, indicating that a restricted repertoire was not the proximate cause of decreased suppression. Transcriptional profiling revealed that CD8+ Tregs possessed a canonical Treg transcriptional signature that was similar to that observed in CD4+ Tregs, yet distinct from conventional CD8+ T cells. Pathway analysis, however, demonstrated that CD8+ Tregs had differential gene expression in pathways involved in cell death and survival. This was further confirmed by detailed mRNA sequence analysis and protein expression studies, which demonstrated that CD8+ Tregs had increased expression of Bim and reduced expression of Mcl-1. Transplantation with CD8+ Foxp3+ Bim-/- Tregs resulted in prolonged Treg survival and reduced GVHD lethality compared with wild-type CD8+ Tregs, providing functional confirmation that increased expression of Bim was responsible for reduced in vivo efficacy. Thus, Bim regulates the survival and suppressive capability of CD8+ Tregs, which may have implications for their use in regulatory T-cell therapy.
© 2018 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29769260      PMCID: PMC6071561          DOI: 10.1182/blood-2017-09-807156

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  53 in total

1.  Requirement of full TCR repertoire for regulatory T cells to maintain intestinal homeostasis.

Authors:  Junko Nishio; Minato Baba; Koji Atarashi; Takeshi Tanoue; Hideo Negishi; Hideyuki Yanai; Sonoko Habu; Shohei Hori; Kenya Honda; Tadatsugu Taniguchi
Journal:  Proc Natl Acad Sci U S A       Date:  2015-09-29       Impact factor: 11.205

2.  The Lower Limit of Regulatory CD4+ Foxp3+ TCRβ Repertoire Diversity Required To Control Autoimmunity.

Authors:  Aixin Yu; Michael J Dee; Dennis Adeegbe; Connor J Dwyer; Norman H Altman; Thomas R Malek
Journal:  J Immunol       Date:  2017-03-06       Impact factor: 5.422

Review 3.  Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy.

Authors:  Peter E Czabotar; Guillaume Lessene; Andreas Strasser; Jerry M Adams
Journal:  Nat Rev Mol Cell Biol       Date:  2014-01       Impact factor: 94.444

Review 4.  Foxp3+ regulatory T cells: differentiation, specification, subphenotypes.

Authors:  Markus Feuerer; Jonathan A Hill; Diane Mathis; Christophe Benoist
Journal:  Nat Immunol       Date:  2009-07       Impact factor: 25.606

5.  Induced regulatory T cells promote tolerance when stabilized by rapamycin and IL-2 in vivo.

Authors:  Ping Zhang; Siok-Keen Tey; Motoko Koyama; Rachel D Kuns; Stuart D Olver; Katie E Lineburg; Mary Lor; Bianca E Teal; Neil C Raffelt; Jyothy Raju; Lucie Leveque; Kate A Markey; Antiopi Varelias; Andrew D Clouston; Steven W Lane; Kelli P A MacDonald; Geoffrey R Hill
Journal:  J Immunol       Date:  2013-10-11       Impact factor: 5.422

Review 6.  Graft-versus-host disease.

Authors:  Warren D Shlomchik
Journal:  Nat Rev Immunol       Date:  2007-05       Impact factor: 53.106

7.  Association of Foxp3 regulatory gene expression with graft-versus-host disease.

Authors:  Yuji Miura; Christopher J Thoburn; Emilie C Bright; Michele L Phelps; Tahiro Shin; Elizabeth C Matsui; William H Matsui; Sally Arai; Ephraim J Fuchs; Georgia B Vogelsang; Richard J Jones; Allan D Hess
Journal:  Blood       Date:  2004-06-01       Impact factor: 22.113

8.  Executioner caspase-3 and caspase-7 are functionally distinct proteases.

Authors:  John G Walsh; Sean P Cullen; Clare Sheridan; Alexander U Lüthi; Christopher Gerner; Seamus J Martin
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-22       Impact factor: 11.205

9.  Sequence signatures and mRNA concentration can explain two-thirds of protein abundance variation in a human cell line.

Authors:  Christine Vogel; Raquel de Sousa Abreu; Daijin Ko; Shu-Yun Le; Bruce A Shapiro; Suzanne C Burns; Devraj Sandhu; Daniel R Boutz; Edward M Marcotte; Luiz O Penalva
Journal:  Mol Syst Biol       Date:  2010-08-24       Impact factor: 11.429

10.  Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3.

Authors:  WanJun Chen; Wenwen Jin; Neil Hardegen; Ke-Jian Lei; Li Li; Nancy Marinos; George McGrady; Sharon M Wahl
Journal:  J Exp Med       Date:  2003-12-15       Impact factor: 14.307

View more
  11 in total

1.  Vitamin C stabilizes CD8+ iTregs and enhances their therapeutic potential in controlling murine GVHD and leukemia relapse.

Authors:  Supinya Iamsawat; Linlu Tian; Anusara Daenthanasanmak; Yongxia Wu; Hung D Nguyen; David Bastian; Xue-Zhong Yu
Journal:  Blood Adv       Date:  2019-12-23

Review 2.  Therapeutic use of regulatory T cells for graft-versus-host disease.

Authors:  Shlomo Elias; Alexander Y Rudensky
Journal:  Br J Haematol       Date:  2019-08-16       Impact factor: 6.998

Review 3.  The Yin and Yang of Targeting KLRG1+ Tregs and Effector Cells.

Authors:  Samantha M Borys; Arup K Bag; Laurent Brossay; Dennis O Adeegbe
Journal:  Front Immunol       Date:  2022-04-29       Impact factor: 8.786

4.  Stabilization of Foxp3 by Targeting JAK2 Enhances Efficacy of CD8 Induced Regulatory T Cells in the Prevention of Graft-versus-Host Disease.

Authors:  Supinya Iamsawat; Anusara Daenthanasanmak; Jessica Heinrichs Voss; Hung Nguyen; David Bastian; Chen Liu; Xue-Zhong Yu
Journal:  J Immunol       Date:  2018-09-21       Impact factor: 5.422

Review 5.  CXCR5+CD8+ T cells: A Review of their Antibody Regulatory Functions and Clinical Correlations.

Authors:  Steven M Elzein; Jason M Zimmerer; Jing L Han; Bryce A Ringwald; Ginny L Bumgardner
Journal:  J Immunol       Date:  2021-06-15       Impact factor: 5.426

Review 6.  A Threshold Model for T-Cell Activation in the Era of Checkpoint Blockade Immunotherapy.

Authors:  Kripa Guram; Sangwoo S Kim; Victoria Wu; P Dominick Sanders; Sandip Patel; Stephen P Schoenberger; Ezra E W Cohen; Si-Yi Chen; Andrew B Sharabi
Journal:  Front Immunol       Date:  2019-03-18       Impact factor: 8.786

Review 7.  Achievement of Tolerance Induction to Prevent Acute Graft-vs.-Host Disease.

Authors:  Govindarajan Thangavelu; Bruce R Blazar
Journal:  Front Immunol       Date:  2019-03-06       Impact factor: 7.561

8.  Blockade of miR-142-3p promotes anti-apoptotic and suppressive function by inducing KDM6A-mediated H3K27me3 demethylation in induced regulatory T cells.

Authors:  Ji Gao; Jian Gu; Xiongxiong Pan; Xiaojie Gan; Zheng Ju; Shaopeng Zhang; Yongxiang Xia; Ling Lu; Xuehao Wang
Journal:  Cell Death Dis       Date:  2019-04-15       Impact factor: 8.469

Review 9.  CD8+ Regulatory T Cell - A Mystery to Be Revealed.

Authors:  Shruti Mishra; Saranya Srinivasan; Chaoyu Ma; Nu Zhang
Journal:  Front Immunol       Date:  2021-08-18       Impact factor: 7.561

Review 10.  Newly Found Peacekeeper: Potential of CD8+ Tregs for Graft-Versus-Host Disease.

Authors:  Weihao Wang; Tao Hong; Xiaoqi Wang; Rui Wang; Yuxuan Du; Qiangguo Gao; Shijie Yang; Xi Zhang
Journal:  Front Immunol       Date:  2021-11-24       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.